Post-approval, non-interventional and observational studies can be used to address questions pertaining to safety surveillance, risk management and efficacy.  Correct study choice and effective execution are paramount to achieving the desired goals.

With a track record for successful analysis and extensive scientific publication, the ICON Late Phase & Outcomes Research division delivers high-impact evidence that explores and demonstrates the value of pharmaceutical, biotechnology, consumer healthcare and medical device products in all global markets, with a focus on maximising return on investment

Our global team of experts provide a full spectrum of market-leading clinical Late Phase research, real-world studies, health economics and patient reported outcomes to support our clients’ product lifecycle, from early stage development, pricing and market access strategies, through regulatory and reimbursement approvals, labeling claims, and in-market support
 

Service offerings include:

• Non-interventional, Observational Research
• Phase IIIb & IV Clinical Trials
• Disease, Product and Exposure Registries
• Safety Surveillance Studies
• Risk Evaluation & Mitigation Strategy (REMS)
• Statistical Design and Analysis
• Epidemiological Studies
• Patient-Reported Outcomes Research
• Health Economic Evaluation
• Indirect Treatment Comparisons
• Strategic Market Access Consulting
• Scientific & Medical Communications
• Translation & Linguistic Validation